NVCR logo

NVCR
NovoCure Ltd

7,771
Mkt Cap
$1.2B
Volume
2,616.00
52W High
$20.06
52W Low
$9.82
PE Ratio
-8.66
NVCR Fundamentals
Price
$10.52
Prev Close
$10.58
Open
$10.46
50D MA
$11.79
Beta
1.43
Avg. Volume
1.35M
EPS (Annual)
-$1.22
P/B
3.50
Rev/Employee
$408,319.63
$1,232.17
Loading...
Loading...
News
all
press releases
Tudor Investment Corp ET AL Raises Stock Position in NovoCure Limited $NVCR
Tudor Investment Corp ET AL boosted its holdings in NovoCure Limited (NASDAQ:NVCR - Free Report) by 140.6% in the third quarter, according to its most recent filing with the SEC. The institutional...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
JPMorgan Chase & Co. Buys 144,024 Shares of NovoCure Limited $NVCR
JPMorgan Chase & Co. lifted its stake in NovoCure Limited (NASDAQ:NVCR - Free Report) by 104.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm...
MarketBeat·9d ago
News Placeholder
SG Americas Securities LLC Boosts Position in NovoCure Limited $NVCR
SG Americas Securities LLC boosted its holdings in NovoCure Limited (NASDAQ:NVCR - Free Report) by 905.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 278,806 shares of the medical equipment provider...
MarketBeat·10d ago
News Placeholder
Novocure to Report First Quarter 2026 Financial Results
Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast...
Business Wire·12d ago
News Placeholder
NovoCure Limited (NASDAQ:NVCR) Given Average Recommendation of "Hold" by Brokerages
Shares of NovoCure Limited (NASDAQ:NVCR - Get Free Report) have earned a consensus recommendation of "Hold" from the seven research firms that are covering the company, MarketBeat reports. One...
MarketBeat·13d ago
News Placeholder
Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of -4.00% and -70.44%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·17d ago
News Placeholder
NVCR Stock Gains After Novocure Announces Positive Topline Results In Metastatic Pancreatic Cancer Therapy Trial
Novocure stated that PANOVA-4 met its pre-specified primary endpoint in the Phase 2 trial, achieving a statistically significant improvement in disease control rate.
Stocktwits·18d ago
News Placeholder
Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
Novocure (NASDAQ: NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq), gemcitabine and nab-paclitaxel (gem/nab-pac) as a first-line treatment for metastatic pancreatic ductal adenocarcinoma...
Business Wire·18d ago
News Placeholder
LENZ Therapeutics, Inc. (LENZ) Reports Q4 Loss, Misses Revenue Estimates
LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of -28.18% and -66.75%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·20d ago
News Placeholder
Tudor Investment Corp ET AL Purchases 354,216 Shares of NovoCure Limited $NVCR
Tudor Investment Corp ET AL lifted its holdings in NovoCure Limited (NASDAQ:NVCR - Free Report) by 140.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 606,070 shares of the medical equipment provider's stock after purch...
MarketBeat·20d ago
<
1
2
...
>

Latest NVCR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.